CHAPTER 70 Cardiopulmonary Bypass
7 List the two basic types of oxygenators
14 Discuss myocardial protection during cardiopulmonary bypass. What elements should be in place to optimize myocardial protection?
16 Review the physiologic responses to cardiopulmonary bypass

18 Develop an appropriate checklist for discontinuing bypass


21 What are some therapies for the patient with impaired cardiac performance or difficulty weaning from cardiopulmonary bypass?
Typical scenarios encountered during the weaning process include reduced vascular resistance (so-called vasoplegia), which often requires vasopressor support. Contractility problems with the heart itself necessitate inotropic agents or possibly an aortic balloon pump to assist in the weaning from bypass. Right heart dysfunction and/or pulmonary hypertension may also complicate weaning from bypass. Agents such as nitric oxide or vasodilator therapy targeted toward the pulmonary system can be useful in this situation. TEE is invaluable in guiding these decisions along with interpretation of the pulmonary artery catheter. Inotropic and vasodilator therapies are discussed in Chapter 15.
22 Review the central nervous system complications of cardiopulmonary bypass
KEY POINTS: Cardiopulmonary Bypass
23 What might be done to decrease the incidence of such complications?



1. Gravlee G. Cardiopulmonary Bypass, Principles and Practice, ed 3. Philadelphia: Lippincott Williams & Wilkins, 2008.
2. Hogue C., Palin C., Arrowsmith J. Cardiopulmonary bypass management and neurologic outcomes: an evidence-based appraisal of current practices. Anesth Analg. 2006;103:21-37.
3. Mora-Mangano C.T., Chow J.L., Kanevsky M. Cardiopulmonary bypass and the anesthesiologist. In: Kaplan J.A., editor. Cardiac anesthesia. ed 5. Philadelphia: Saunders Elsevier; 2006:893-935.
4. Murphy G.J., Angelini G.D. Side effects of cardiopulmonary bypass: what is the reality? J Card Surg. 2004;19:481-488.